35709-36-5

Basic information

• Product Name: 4-chloro-N-benzylisatoic anhydride
• Synonyms: 4-chloro-N-benzylisatoic anhydride
• CAS NO: 35709-36-5
• Molecular Weight: 287.702
• Mol File: 35709-36-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-chloro-N-benzylisatoic anhydride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-N-benzylisatoic anhydride(35709-36-5)
• EPA Substance Registry System: 4-chloro-N-benzylisatoic anhydride(35709-36-5)

Safety Data

• Hazardous Substances Data: 35709-36-5(Hazardous Substances Data)

Upstream product

• 40928-13-0 4-chloroisatoic anhydride 
• 100-39-0 benzyl bromide 

Downstream Products

• 1429014-27-6 1-benzyl-7-chloro-N'-dodecanoyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbohydrazide 
• 1429014-26-5 1-benzyl-7-chloro-4-hydroxy-N'-octanoyl-2-oxo-1,2-dihydroquinoline-3-carbohydrazide 
• 1429014-07-2 ethyl 1-benzyl-7-chloro-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate 
• 108202-18-2 11-Benzyl-9-chloro-1,2,3,4,5,11-hexahydro-azepino[2,3-b]quinolin-6-one 

Relevant articles and documents

Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases

Glycogen synthase kinase 3 β (GSK-3β) is a central target in several unmet diseases. To increase the specificity of GSK-3β inhibitors in chronic treatments, we developed small molecules allowing subtle modulation of GSK-3β activity. Design synthesis, structure-Activity relationships, and binding mode of quinoline-3-carbohydrazide derivatives as allosteric modulators of GSK-3β are presented here. Furthermore, we show how allosteric binders may overcome the β-catenin side effects associated with strong GSK-3β inhibition. The therapeutic potential of some of these modulators has been tested in human samples from patients with congenital myotonic dystrophy type 1 (CDM1) and spinal muscular atrophy (SMA) patients. We found that compound 53 improves delayed myogenesis in CDM1 myoblasts, while compounds 1 and 53 have neuroprotective properties in SMA-derived cells. These findings suggest that the allosteric modulators of GSK-3β may be used for future development of drugs for DM1, SMA, and other chronic diseases where GSK-3β inhibition exhibits therapeutic effects.

HETEROCYCLIC GSK-3 ALLOSTERIC MODULATORS

The invention relates to heterocyclic derivatives of substituted quinolines as allosteric inhibitors of the glycogen synthase kinase 3 (GSK-3) enzyme. Thus, said compounds can be used in the production of a drug for the treatment and/or prevention of diseases in which GSK-3 is involved, such as: neurodegenerative diseases, inflammatory diseases, cancer and diabetes, as well as to promote a plurality of regenerative processes..